Upadacitinib therapy in refractory inflammatory myositis: a case series of 10 patients
Authors' conclusion
Upadacitinib appears to be effective in targeting cutaneous manifestations of refractory inflammatory DM.
Study context
- Population
- Patients with refractory inflammatory myositis treated with upadacitinib, single urban centre in Vancouver, Canada, September 2020 to June 2023
- Participants
- 10 patients
- Exposure
- Classic dermatomyositis (DM) vs amyopathic DM (ADM) vs Antisynthetase syndrome
- Classic DMn = 5
- ADMn = 3
- Antisynthetase syndromen = 2
- Outcome
- Cutaneous improvement (classic DM and ADM aggregate)
Methodological detailssingle-centre, retrospective chart review, Patients failed an average of four immunosuppressants before upadacitinib; three had prior JAKi therapy with tofacitinib
- Single-centre
- Retrospective chart review
- Patients failed an average of four immunosuppressants before upadacitinib; three had prior JAKi therapy with tofacitinib
Main finding
As reported in the abstract
- Upadacitinib offered clinically and statistically significant cutaneous improvement in the classic DM and ADM aggregate group
- Lack of active muscle disease at baseline precluded analysis of effect on muscle weakness
Observational data: associations, not effects.
Further findings
Remained on upadacitinib at end of study period
- Patients remaining on upadacitinib
- 9
Safety
Discontinuation due to severe facial acne
- Patients discontinuing upadacitinib due to severe facial acne
- 1
Original publication
Upadacitinib therapy in refractory inflammatory myositis: a case series of 10 patients. RMD Open. Published 18 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →